Published 10 days ago • loading... • Updated 10 days ago

Lilly, Novo expand DTC reach of obesity meds after compound win

Summary by PharmaVOICE

The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.

1 Articles

All

Left

Center

Right

The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.

10 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated9 days agoBias Distribution

100% Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

PharmaVOICE broke the news in 10 days ago on Monday, March 24, 2025.

Sources are mostly out of (0)